BLSI Boston Life Sciences (MM)

HOPKINTON, Oct. 30 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that Ken Rice, Executive Vice President and Chief Financial Officer of Boston Life Sciences, Inc., will be presenting a Company update at the Mass Opportunities Conference on Thursday, November 2 from 3:50pm - 4:10pm EST in the Wellesley Meeting Room. There will be a Q&A session immediately following the presentation from 4:10pm - 4:40pm EST in the Amherst Room. The conference is being held on November 2 at the Hilton Boston Logan Airport in Boston, Massachusetts. The Boston Life Sciences presentation will be available by webcast. Access to the webcast will be available within the Investor Relations section of the Boston Life Sciences website at http://www.bostonlifesciences.com/. About Boston Life Sciences, Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston. ALTROPANE is a registered trademark of Boston Life Sciences, Inc. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT: Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360 ext 224, Web site: http://www.bostonlifesciences.com/

Copyright